Innate Pharma shares plunge after Phase 1 data for Nectin‑4 ADC IPH4502
Innate Pharma disclosed initial Phase 1 results for its Nectin‑4‑targeting antibody‑drug conjugate IPH4502 at a major oncology symposium on 18 Nov 2026. The study, which enrolled 76 patients with advanced solid tumours, identified a tolerable dose of 3.6 mg per kilogram given every three weeks, with stomatitis being the only dose‑limiting side effect. An objective response rate of 33 % was observed in non‑urothelial cancers, while disease control in urothelial cancer reached 68.4 % but only three partial responses were seen. The announcement triggered a sharp sell‑off in the stock.
Why it matters
The market reaction lowered the share price by about 21 % to $1.05, erasing a large portion of the company's market value and pushing the stock to a new 52‑week low. BTIG’s $9.00 price target, previously cited by analysts, now appears out of reach given the modest efficacy signals.
Key facts
- 1The Phase 1 dose‑escalation trial included 76 patients with advanced solid tumours across more than ten tumour types. finanznachrichten.de
- 2The highest tolerated dose was determined to be 3.6 mg/kg administered once every three weeks, with stomatitis as the sole dose‑limiting toxicity. finanznachrichten.de
- 3At that dose, an objective response rate of 33 % (2 of 6 patients) was recorded in non‑urothelial tumours. finanznachrichten.de
- 4In urothelial cancer, the unconfirmed disease‑control rate was 68.4 % (95 % CI 46.0‑84.6). finanznachrichten.de
- 5Shares fell 21.1 % in mid‑day trading to $1.05 after the data release. investing.com
- 6BTIG maintained a Buy rating with a $9.00 price target before the readout. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.